Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-07-18
Target enrollment:
Participant gender:
Summary
The study will evaluate how safe and effective abemaciclib is when given to participants
whose metastatic prostate cancer progresses after they had received several previous
treatments.